Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Interferon α2b in Children with Mild-to-Moderate COVID-19
NCT05381363Phase 2Terminated
- Sponsor
- Children's Hospital of Fudan University
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Inhaled Interferon α2b with Standard of Care (2 arms). Primary endpoint: Days requiring isolation. Started Jan 2022; status: terminated.
02
Drugs
interferon alfa-2b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05381363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381363.